TSHA102 is being evaluated in the REVEAL Phase 12 trial  a firstinhuman openlabel randomized doseescalation and doseexpansion study evaluating the safety and preliminary efficacy of TSHA102 in adult females with Rett syndrome due to MECP2 lossoffunction mutation